spironolactone has been researched along with Chronic Illness in 141 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " spironolactone on left ventricular systolic function by measuring left ventricle ejection fraction (LVEF) in patients with chronic heart failure, especially their effect on preventing hospitalization, reducing mortality, and improving clinical status among patients with chronic HF." | 9.69 | The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. ( Durak-Nalbantic, A; Karic, A; Naser, N; Sabanovic-Bajramovic, N, 2023) |
| "These findings suggest that oral eplerenone therapy is safe and potentially effective in the treatment of chronic central serous chorioretinopathy with persistent subretinal fluid." | 9.27 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). ( Adam, MK; Chiang, A; Fineman, MS; Hsu, J; Kaiser, RS; Pitcher, JD; Rahimy, E; Samara, WA; Shahlaee, A; Spirn, MJ; Vander, JF, 2018) |
| "To characterize eplerenone pharmacokinetics (PK) in Japanese chronic heart failure (CHF) patients and to estimate the impact of factors that may affect eplerenone PK, population pharmacokinetic (PPK) analysis was conducted." | 9.24 | Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. ( Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q, 2017) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 9.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 9.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "This study was designed to assess the effects of spironolactone (SP) on left ventricular (LV) function and exercise tolerance in patients with chronic heart failure (CHF)." | 9.10 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. ( Brighetti, G; Cicoira, M; Franceschini, L; Golia, G; Marino, P; Rossi, A; Zanolla, L; Zardini, P, 2002) |
| "The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality." | 9.09 | Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. ( Farquharson, CA; Struthers, AD, 2000) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 9.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist that has been recently included in the treatment of patients with chronic heart failure (CHF) and reduced systolic function." | 8.91 | Eplerenone in chronic heart failure with depressed systolic function. ( Iellamo, F; Volterrani, M, 2015) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 8.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 8.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| "To assess the morphological and functional outcome of oral eplerenone for treatment of patients with chronic central serous chorioretinopathy (CSC) in a real life experience." | 8.02 | Eplerenone for treatment of chronic central serous chorioretinopathy. ( Abdin, AD; Fraenkel, D; Langenbucher, A; Seitz, B; Suffo, S, 2021) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 7.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC)." | 7.85 | Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. ( Cohen, S; Goldenberg, D; Goldstein, M; Guzner-Gur, H; Habot-Wilner, Z; Loewenstein, A; Martinez, MR; Nutman, A; Schwartz, R; Shulman, S, 2017) |
| "To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)." | 7.83 | Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016) |
| "To evaluate the efficacy of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic central serous chorioretinopathy (CSCR)." | 7.83 | [Eplerenone treatment in chronic central serous chorioretinopathy]. ( Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V, 2016) |
| "Aspirin use in patients with chronic systolic heart failure and mild symptoms did not substantially reduce the overall beneficial effects of the MRA eplerenone contrary to what has been described in some studies with ACE inhibitors." | 7.83 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. ( Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2016) |
| "The objective of this study was to determine the cost-effectiveness of eplerenone compared with usual care in patients with chronic heart failure and New York Heart Association (NYHA) Class II symptoms." | 7.83 | Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2016) |
| "To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR)." | 7.81 | Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. ( Elliott, KS; Fineman, MS; Fischer, DH; Hsu, J; Pitcher, JD; Regillo, CD; Salz, DA; Spirn, MJ; Vander, JF, 2015) |
| " Spironolactone is well known to have an anti-aldosteronergic effect, and this agent could improve cardiac sympathetic nerve activity (CSNA) in patients with chronic heart failure (CHF)." | 7.79 | Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2013) |
| "To assess how well heart failure patients tolerate spironolactone in routine clinical practice." | 7.72 | Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. ( Gillespie, ND; Struthers, AD; Witham, MD, 2004) |
| "The association with spironolactone (25 mg/day) with the standard therapy for heart failure produces a remarkable net benefit in monetary terms." | 7.71 | [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure]. ( Alvarez, JS; Vílchez, FG, 2001) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 7.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 7.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 6.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| " spironolactone on left ventricular systolic function by measuring left ventricle ejection fraction (LVEF) in patients with chronic heart failure, especially their effect on preventing hospitalization, reducing mortality, and improving clinical status among patients with chronic HF." | 5.69 | The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. ( Durak-Nalbantic, A; Karic, A; Naser, N; Sabanovic-Bajramovic, N, 2023) |
| "Eplerenone is a novel selective aldosterone blocker." | 5.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| "These findings suggest that oral eplerenone therapy is safe and potentially effective in the treatment of chronic central serous chorioretinopathy with persistent subretinal fluid." | 5.27 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). ( Adam, MK; Chiang, A; Fineman, MS; Hsu, J; Kaiser, RS; Pitcher, JD; Rahimy, E; Samara, WA; Shahlaee, A; Spirn, MJ; Vander, JF, 2018) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "To characterize eplerenone pharmacokinetics (PK) in Japanese chronic heart failure (CHF) patients and to estimate the impact of factors that may affect eplerenone PK, population pharmacokinetic (PPK) analysis was conducted." | 5.24 | Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. ( Oishi, M; Sweeney, K; Tomono, Y; Zhao, Q, 2017) |
| "To evaluate the macular thickness, choroidal thickness, and visual acuity changes in eyes of patients with bilateral chronic central serous chorioretinopathy during eplerenone treatment." | 5.24 | MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. ( Ecsedy, M; Gergely, R; Kovács, I; Nagy, ZZ; Papp, A; Récsán, Z; Resch, M; Schneider, M, 2017) |
| "Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs." | 5.19 | Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. ( Anker, SD; Doehner, W; Hisatome, I; Kato, M; Kinugasa, Y; Ogino, K; Yamamoto, K, 2014) |
| "To evaluate efficacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K+]-binding polymer) on serum K+ levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone." | 5.15 | Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. ( Anker, SD; Bushinsky, DA; Huang, IZ; Kitzman, DW; Pitt, B; Zannad, F, 2011) |
| "We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia." | 5.14 | Spironolactone in chronic hemodialysis patients improves cardiac function. ( Eshaghian, A; Garakyaraghi, M; Ghassami, M; Mortazavi, M; Pourmoghadas, A; Seirafian, S; Shahidi, S; Taheri, S, 2009) |
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 5.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator." | 5.11 | Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. ( Boehmer, J; Bristow, MR; Carson, P; De Marco, T; DeMets, D; DeVries, DW; DiCarlo, L; Feldman, AM; Kass, DA; Krueger, S; Saxon, LA; White, BG, 2004) |
| "This study was designed to assess the effects of spironolactone (SP) on left ventricular (LV) function and exercise tolerance in patients with chronic heart failure (CHF)." | 5.10 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. ( Brighetti, G; Cicoira, M; Franceschini, L; Golia, G; Marino, P; Rossi, A; Zanolla, L; Zardini, P, 2002) |
| "The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality." | 5.09 | Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. ( Farquharson, CA; Struthers, AD, 2000) |
| "Plasma levels of canrenone and androgen receptor-active materials (ARM) were determined during long-term oral K-canrenoate or spironolactone therapy in cirrhotics with chronic recurrent ascites." | 5.06 | Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy. ( Andriulli, A; Armanini, D; Arrigoni, A; Buzzetti, G; Gindro, T; Karbowiak, I, 1989) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 5.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "Eplerenone is a selective mineralocorticoid receptor antagonist that has been recently included in the treatment of patients with chronic heart failure (CHF) and reduced systolic function." | 4.91 | Eplerenone in chronic heart failure with depressed systolic function. ( Iellamo, F; Volterrani, M, 2015) |
| "In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study." | 4.82 | [Aldosterone and its antagonists in heart failure]. ( Badoual, T; Cachin, JC; Castaigne, A; Hittinger, L; Le Corvoisier, P; Lopes, ME; Merlet, P; Su, JB; Tabet, JY, 2003) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 4.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "To assess the morphological and functional outcome of oral eplerenone for treatment of patients with chronic central serous chorioretinopathy (CSC) in a real life experience." | 4.02 | Eplerenone for treatment of chronic central serous chorioretinopathy. ( Abdin, AD; Fraenkel, D; Langenbucher, A; Seitz, B; Suffo, S, 2021) |
| "The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats." | 3.96 | Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. ( Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A, 2020) |
| "To evaluate the efficacy and safety of eplerenone for chronic nonresolving central serous chorioretinopathy (CSC)." | 3.85 | Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. ( Cohen, S; Goldenberg, D; Goldstein, M; Guzner-Gur, H; Habot-Wilner, Z; Loewenstein, A; Martinez, MR; Nutman, A; Schwartz, R; Shulman, S, 2017) |
| "To evaluate the efficacy of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic central serous chorioretinopathy (CSCR)." | 3.83 | [Eplerenone treatment in chronic central serous chorioretinopathy]. ( Denis, D; Gascon, P; Ho Wang Yin, G; Hoffart, L; Matonti, F; Sampo, M; Soler, V, 2016) |
| "The objective of this study was to determine the cost-effectiveness of eplerenone compared with usual care in patients with chronic heart failure and New York Heart Association (NYHA) Class II symptoms." | 3.83 | Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2016) |
| "Aspirin use in patients with chronic systolic heart failure and mild symptoms did not substantially reduce the overall beneficial effects of the MRA eplerenone contrary to what has been described in some studies with ACE inhibitors." | 3.83 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. ( Chin, KL; Collier, TJ; Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Swedberg, K; Turgonyi, E; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2016) |
| "To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)." | 3.83 | Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016) |
| "To assess the effect of eplerenone on macular structure and function in patients with chronic central serous chorioretinopathy." | 3.83 | The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. ( Filemonowicz-Skoczek, A; Karska-Basta, I; Kubicka-Trzaska, A; Ozog-Baran, J; Pociej-Marciak, W; Romanowska-Dixon, B, 2016) |
| "To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR)." | 3.81 | Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. ( Elliott, KS; Fineman, MS; Fischer, DH; Hsu, J; Pitcher, JD; Regillo, CD; Salz, DA; Spirn, MJ; Vander, JF, 2015) |
| "We sought to evaluate the cost effectiveness of eplerenone compared with placebo in patients with chronic systolic heart failure and NYHA class II symptoms." | 3.80 | Cost effectiveness of eplerenone in patients with chronic heart failure. ( Ademi, Z; Krum, H; Liew, D; Pasupathi, K, 2014) |
| " Spironolactone is well known to have an anti-aldosteronergic effect, and this agent could improve cardiac sympathetic nerve activity (CSNA) in patients with chronic heart failure (CHF)." | 3.79 | Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2013) |
| " Fifty-five rats with heart failure were then randomized in 5 groups: sham, MI, and MI treated for 4 weeks with spironolactone (10 mg·kg·d), atenolol (1 mg·kg·d), or both." | 3.78 | Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts. ( Callebert, J; Champ-Rigot, L; Delcayre, C; Gomes, S; Milliez, P; Samuel, JL, 2012) |
| "The paper contains presentation of basics of clinical pharmacology of aldosterone receptor blockers specifically that of spironolactone and eplerenone, and discussion of results of 2 large randomized placebo controlled trials which showed that long term use of aldosterone receptor blockers allowed to improve prognosis of patients with severe chronic heart failure and postinfarction systolic left ventricular dysfunction, and to reduce requirements in repetitive hospitalizations." | 3.73 | [The place of aldosterone receptor blockers in the treatment of chronic heart failure]. ( , 2005) |
| "To assess how well heart failure patients tolerate spironolactone in routine clinical practice." | 3.72 | Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. ( Gillespie, ND; Struthers, AD; Witham, MD, 2004) |
| "The association with spironolactone (25 mg/day) with the standard therapy for heart failure produces a remarkable net benefit in monetary terms." | 3.71 | [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure]. ( Alvarez, JS; Vílchez, FG, 2001) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 3.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| " In six patients with Bartter's syndrome, four with pseudo-Bartter's syndrome, and twenty with essential hypertension (EH) chronically treated with chlorthalidone, serum potassium (serum K+) and extracellular fluid volume (ECFV) were decreased, while plasma volume (PV) and blood volume (BV) were normal (see Table 1 for means, standard deviations, and levels of significance)." | 3.67 | Blood to interstitial fluid volume ratio in chronic hypokalaemic states. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; Hené, RJ; Koomans, HA; Roos, JC; Van Shaik, BA, 1985) |
| "In 8 out of 20 patients with chronic liver disease ascites was controlled with metolazone, 10 required additional amiloride or spironolactone to achieve control, and 2 were resistant to all diuretic therapy." | 3.65 | Use of metolazone in the treatment of ascites due to liver disease. ( Hillenbrand, P; Sherlock, S, 1971) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 3.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that is primarily used to treat hypertension." | 2.82 | Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends. ( Abdelhakeem, E; El-Nabarawi, M; Shamma, R, 2022) |
| "Thiamine levels were determined using the erythrocyte transketolase activity." | 2.73 | Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. ( Albanesi Filho, FM; de Albuquerque, DC; Rocha, RM; Silva, GV; Tura, BR, 2008) |
| "The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310." | 2.68 | Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. ( Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P, 1997) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| "Heart failure is increasing in incidence and prevalence and is predominantly a condition of the elderly, which confers significant morbidity and mortality risks and places an enormous economic burden on the health care system and society." | 2.42 | Diagnosis and management of heart failure in the long-term care setting. ( Gaulden, L, 2003) |
| "Chronic heart failure is widely recognised as a common and escalating problem that causes major disability and often shortens life." | 2.42 | Drug therapy in chronic heart failure. ( Cowley, AJ; McKenzie, DB, 2003) |
| " This therapeutic association is very logical, effective and allows reduction in the dosage of the diuretic." | 2.39 | [Classic treatment of chronic heart insufficiency. What if new?]. ( Agnola, D; Aumont, MC; Juliard, JM; Karrillon, G, 1995) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Spironolactone treatment decreased the total heart weight." | 1.38 | Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation. ( Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A, 2012) |
| "One case of acute renal failure and three cases of significant hyperkalemia occurred." | 1.38 | Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. ( Acelajado, MC; Calhoun, DA; Cartmill, FR; Cofield, SS; Dell'Italia, LJ; Dudenbostel, T; Oparil, S; Pisoni, R, 2012) |
| "The Impact-Reco programme found an improvement in prescription rates and in the dosage of neurohumoral antagonists in French outpatients with stable CHF." | 1.35 | Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. ( Assyag, P; Clerson, P; de Groote, P; Demil, N; Ducardonnet, A; Galinier, M; Isnard, R; Jondeau, G; Komajda, M; Thebaut, JF, 2009) |
| "While hyperkalemia was more common initially, hypokalemia was more frequent with long-term use." | 1.33 | Clinical experience with spironolactone in pediatrics. ( Buck, ML, 2005) |
| "Eplerenone is a novel selective aldosterone blocker." | 1.31 | Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. ( Goldstein, S; McMahon, EG; Mishima, T; Morita, H; Rudolph, AE; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A, 2002) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (24.11) | 18.7374 |
| 1990's | 12 (8.51) | 18.2507 |
| 2000's | 42 (29.79) | 29.6817 |
| 2010's | 48 (34.04) | 24.3611 |
| 2020's | 5 (3.55) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhakeem, E | 1 |
| El-Nabarawi, M | 1 |
| Shamma, R | 1 |
| Naser, N | 1 |
| Durak-Nalbantic, A | 1 |
| Sabanovic-Bajramovic, N | 1 |
| Karic, A | 1 |
| Kutsche, HS | 1 |
| Schreckenberg, R | 1 |
| Weber, M | 1 |
| Hirschhäuser, C | 1 |
| Rohrbach, S | 1 |
| Li, L | 1 |
| Niemann, B | 1 |
| Schulz, R | 1 |
| Schlüter, KD | 1 |
| Krasnova, M | 1 |
| Kulikov, A | 1 |
| Okovityi, S | 1 |
| Ivkin, D | 1 |
| Karpov, A | 1 |
| Kaschina, E | 1 |
| Smirnov, A | 1 |
| Fraenkel, D | 1 |
| Suffo, S | 1 |
| Langenbucher, A | 1 |
| Seitz, B | 1 |
| Abdin, AD | 1 |
| Rahimy, E | 1 |
| Pitcher, JD | 2 |
| Hsu, J | 2 |
| Adam, MK | 1 |
| Shahlaee, A | 1 |
| Samara, WA | 1 |
| Vander, JF | 2 |
| Kaiser, RS | 1 |
| Chiang, A | 1 |
| Spirn, MJ | 2 |
| Fineman, MS | 2 |
| Schwartz, R | 1 |
| Habot-Wilner, Z | 1 |
| Martinez, MR | 1 |
| Nutman, A | 1 |
| Goldenberg, D | 1 |
| Cohen, S | 1 |
| Shulman, S | 1 |
| Guzner-Gur, H | 1 |
| Loewenstein, A | 1 |
| Goldstein, M | 1 |
| Pociej-Marciak, W | 1 |
| Karska-Basta, I | 1 |
| Ozog-Baran, J | 1 |
| Kubicka-Trzaska, A | 1 |
| Filemonowicz-Skoczek, A | 1 |
| Romanowska-Dixon, B | 1 |
| Zola, M | 1 |
| Daruich, A | 1 |
| Matet, A | 1 |
| Mantel, I | 1 |
| Behar-Cohen, F | 1 |
| Brunner-La Rocca, HP | 1 |
| Linssen, GC | 1 |
| Smeele, FJ | 1 |
| van Drimmelen, AA | 1 |
| Schaafsma, HJ | 1 |
| Westendorp, PH | 1 |
| Rademaker, PC | 1 |
| van de Kamp, HJ | 1 |
| Hoes, AW | 1 |
| Brugts, JJ | 1 |
| Pascual-Figal, DA | 1 |
| Caballero, L | 1 |
| Bayes-Genis, A | 1 |
| Gonzalez-Juanatey, JR | 1 |
| Vazquez, R | 1 |
| Bayes de Luna, A | 1 |
| Cinca, J | 1 |
| Ferreira, JP | 1 |
| Santos, M | 1 |
| Almeida, S | 1 |
| Marques, I | 1 |
| Bettencourt, P | 2 |
| Carvalho, H | 1 |
| Salavastru, CM | 1 |
| Fritz, K | 1 |
| Tiplica, GS | 1 |
| Ogino, K | 1 |
| Kinugasa, Y | 1 |
| Kato, M | 2 |
| Yamamoto, K | 1 |
| Hisatome, I | 1 |
| Anker, SD | 3 |
| Doehner, W | 1 |
| Maier, M | 1 |
| Stumpfe, S | 1 |
| Feucht, N | 1 |
| Strobl, P | 1 |
| Rath, V | 1 |
| Lohmann, CP | 1 |
| Lindblad, AJ | 1 |
| Allan, GM | 1 |
| Ademi, Z | 2 |
| Pasupathi, K | 2 |
| Krum, H | 6 |
| Liew, D | 3 |
| Breukink, MB | 1 |
| den Hollander, AI | 1 |
| Keunen, JE | 1 |
| Boon, CJ | 1 |
| Hoyng, CB | 1 |
| Otero, MJ | 1 |
| Moreno-Gómez, AM | 1 |
| Santos-Ramos, B | 1 |
| Agra, Y | 1 |
| Sun, QL | 1 |
| Li, M | 1 |
| Rui, HL | 1 |
| Chen, YP | 1 |
| Salz, DA | 1 |
| Regillo, CD | 1 |
| Elliott, KS | 1 |
| Fischer, DH | 1 |
| Volterrani, M | 1 |
| Iellamo, F | 1 |
| Leisser, C | 1 |
| Hirnschall, N | 1 |
| Hackl, C | 1 |
| Plasenzotti, P | 1 |
| Findl, O | 1 |
| Chin, KL | 1 |
| Collier, TJ | 1 |
| Pitt, B | 5 |
| McMurray, JJ | 2 |
| Swedberg, K | 2 |
| van Veldhuisen, DJ | 4 |
| Pocock, SJ | 1 |
| Vincent, J | 2 |
| Turgonyi, E | 1 |
| Zannad, F | 4 |
| Sato, N | 1 |
| Ajioka, M | 1 |
| Yamada, T | 2 |
| Myoishi, M | 1 |
| Kim, SY | 2 |
| Nowack, C | 2 |
| Kolkhof, P | 2 |
| Shiga, T | 1 |
| Filippatos, G | 1 |
| Böhm, M | 1 |
| Gheorghiade, M | 1 |
| Køber, L | 1 |
| Maggioni, AP | 1 |
| Ponikowski, P | 1 |
| Voors, AA | 3 |
| Palombo, G | 1 |
| Kimmeskamp-Kirschbaum, N | 1 |
| Pieper, A | 1 |
| Cakir, B | 1 |
| Fischer, F | 1 |
| Ehlken, C | 1 |
| Bühler, A | 1 |
| Stahl, A | 1 |
| Schlunck, G | 1 |
| Böhringer, D | 1 |
| Agostini, H | 1 |
| Lange, C | 1 |
| Sampo, M | 1 |
| Soler, V | 1 |
| Gascon, P | 1 |
| Ho Wang Yin, G | 1 |
| Hoffart, L | 1 |
| Denis, D | 1 |
| Matonti, F | 1 |
| Bristow, MR | 2 |
| Saxon, LA | 2 |
| Feldman, AM | 2 |
| Mei, C | 1 |
| Anderson, SA | 1 |
| DeMets, DL | 1 |
| Gergely, R | 1 |
| Kovács, I | 1 |
| Schneider, M | 1 |
| Resch, M | 1 |
| Papp, A | 1 |
| Récsán, Z | 1 |
| Nagy, ZZ | 1 |
| Ecsedy, M | 1 |
| Hoss, S | 1 |
| Elizur, Y | 1 |
| Luria, D | 1 |
| Keren, A | 1 |
| Lotan, C | 1 |
| Gotsman, I | 1 |
| Oishi, M | 1 |
| Tomono, Y | 1 |
| Zhao, Q | 1 |
| Sweeney, K | 1 |
| Tregubov, VG | 1 |
| Kanorskiy, SG | 1 |
| Pokrovskiy, VM | 1 |
| Rocha, RM | 1 |
| Silva, GV | 1 |
| de Albuquerque, DC | 1 |
| Tura, BR | 1 |
| Albanesi Filho, FM | 1 |
| Renke, M | 2 |
| Tylicki, L | 2 |
| Knap, N | 1 |
| Rutkowski, P | 2 |
| Neuwelt, A | 1 |
| Larczynski, W | 2 |
| Wozniak, M | 1 |
| Rutkowski, B | 2 |
| de Groote, P | 1 |
| Isnard, R | 1 |
| Clerson, P | 1 |
| Jondeau, G | 1 |
| Galinier, M | 1 |
| Assyag, P | 1 |
| Demil, N | 1 |
| Ducardonnet, A | 1 |
| Thebaut, JF | 1 |
| Komajda, M | 1 |
| Waanders, F | 1 |
| Rienstra, H | 1 |
| Boer, MW | 1 |
| Zandvoort, A | 1 |
| Rozing, J | 1 |
| Navis, G | 1 |
| van Goor, H | 1 |
| Hillebrands, JL | 1 |
| Preston, RA | 1 |
| Afshartous, D | 1 |
| Garg, D | 1 |
| Medrano, S | 1 |
| Alonso, AB | 1 |
| Rodriguez, R | 1 |
| Kamalov, G | 1 |
| Deshmukh, PA | 1 |
| Baburyan, NY | 1 |
| Gandhi, MS | 1 |
| Johnson, PL | 1 |
| Ahokas, RA | 1 |
| Bhattacharya, SK | 1 |
| Sun, Y | 1 |
| Gerling, IC | 1 |
| Weber, KT | 1 |
| Taheri, S | 1 |
| Mortazavi, M | 1 |
| Shahidi, S | 1 |
| Pourmoghadas, A | 1 |
| Garakyaraghi, M | 1 |
| Seirafian, S | 1 |
| Eshaghian, A | 1 |
| Ghassami, M | 1 |
| Kandula, P | 1 |
| Shah, R | 1 |
| Lopes, R | 1 |
| Lourenco, P | 1 |
| Mascarenhas, J | 1 |
| Azevedo, A | 1 |
| Yamaji, M | 1 |
| Tsutamoto, T | 1 |
| Kawahara, C | 1 |
| Nishiyama, K | 1 |
| Yamamoto, T | 3 |
| Fujii, M | 1 |
| Horie, M | 1 |
| Ando, K | 1 |
| Ohtsu, H | 1 |
| Arakawa, Y | 1 |
| Kubota, K | 1 |
| Yamaguchi, T | 1 |
| Nagase, M | 2 |
| Yamada, A | 1 |
| Fujita, T | 2 |
| Drexler, H | 1 |
| Shi, H | 1 |
| Funder, JW | 1 |
| Tiryaki, O | 1 |
| Usalan, C | 1 |
| Buyukhatipoglu, H | 1 |
| Edwards, NC | 1 |
| Ferro, CJ | 1 |
| Kirkwood, H | 1 |
| Chue, CD | 1 |
| Young, AA | 1 |
| Stewart, PM | 1 |
| Steeds, RP | 1 |
| Townend, JN | 1 |
| Sundar, U | 1 |
| Lakkas, Y | 1 |
| Asole, D | 1 |
| Vaidya, M | 1 |
| Abolghasmi, R | 1 |
| Taziki, O | 1 |
| Bushinsky, DA | 1 |
| Kitzman, DW | 1 |
| Huang, IZ | 1 |
| Pisoni, R | 1 |
| Acelajado, MC | 1 |
| Cartmill, FR | 1 |
| Dudenbostel, T | 1 |
| Dell'Italia, LJ | 1 |
| Cofield, SS | 1 |
| Oparil, S | 1 |
| Calhoun, DA | 1 |
| Brem, AS | 1 |
| Morris, DJ | 1 |
| Gong, R | 1 |
| Zhou, X | 1 |
| Crook, MF | 1 |
| Sharif-Rodriguez, W | 1 |
| Zhu, Y | 1 |
| Ruben, Z | 1 |
| Pan, Y | 1 |
| Urosevic-Price, O | 1 |
| Wang, L | 1 |
| Flattery, AM | 1 |
| Forrest, G | 1 |
| Szeto, D | 1 |
| Zhao, H | 1 |
| Roy, S | 1 |
| Forrest, MJ | 1 |
| Kasama, S | 1 |
| Toyama, T | 1 |
| Sumino, H | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Minami, K | 1 |
| Ichikawa, S | 1 |
| Matsumoto, N | 1 |
| Sato, Y | 1 |
| Kurabayashi, M | 1 |
| Milliez, P | 1 |
| Gomes, S | 1 |
| Champ-Rigot, L | 1 |
| Callebert, J | 1 |
| Samuel, JL | 1 |
| Delcayre, C | 1 |
| Zendaoui, A | 1 |
| Lachance, D | 1 |
| Roussel, E | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Kamyshnikova, LA | 1 |
| Efremova, OA | 1 |
| Hu, LJ | 1 |
| Chen, YQ | 1 |
| Deng, SB | 1 |
| Du, JL | 1 |
| She, Q | 1 |
| Suzuki, G | 1 |
| Morita, H | 1 |
| Mishima, T | 1 |
| Sharov, VG | 1 |
| Todor, A | 1 |
| Tanhehco, EJ | 1 |
| Rudolph, AE | 1 |
| McMahon, EG | 1 |
| Goldstein, S | 1 |
| Sabbah, HN | 1 |
| Feria, I | 1 |
| Pichardo, I | 1 |
| Juárez, P | 1 |
| Ramírez, V | 1 |
| González, MA | 1 |
| Uribe, N | 1 |
| García-Torres, R | 1 |
| López-Casillas, F | 1 |
| Gamba, G | 1 |
| Bobadilla, NA | 1 |
| Jourdain, P | 1 |
| Funck, F | 1 |
| Bellorini, M | 1 |
| Guillard, N | 1 |
| Loiret, J | 1 |
| Thebault, B | 1 |
| Desnos, M | 1 |
| Duboc, D | 1 |
| Lopes, ME | 1 |
| Le Corvoisier, P | 1 |
| Tabet, JY | 1 |
| Su, JB | 1 |
| Badoual, T | 1 |
| Cachin, JC | 1 |
| Merlet, P | 1 |
| Castaigne, A | 1 |
| Hittinger, L | 1 |
| McKee, SP | 1 |
| Leslie, SJ | 1 |
| LeMaitre, JP | 1 |
| Webb, DJ | 1 |
| Denvir, MA | 1 |
| KATO, E | 1 |
| OSAWA, S | 1 |
| WAKASUGI, A | 1 |
| KIRIU, Y | 1 |
| ATO, T | 1 |
| MITSUNO, K | 1 |
| ITAZU, Y | 1 |
| Gaulden, L | 1 |
| McKenzie, DB | 1 |
| Cowley, AJ | 1 |
| Jolobe, O | 1 |
| Boehmer, J | 1 |
| Krueger, S | 1 |
| Kass, DA | 1 |
| De Marco, T | 1 |
| Carson, P | 1 |
| DiCarlo, L | 1 |
| DeMets, D | 1 |
| White, BG | 1 |
| DeVries, DW | 1 |
| Kochsiek, K | 1 |
| Witham, MD | 1 |
| Gillespie, ND | 1 |
| Struthers, AD | 4 |
| Kuster, GM | 1 |
| Kotlyar, E | 1 |
| Rude, MK | 1 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Colucci, WS | 1 |
| Sam, F | 1 |
| Watz, R | 1 |
| Ekstrand, AB | 1 |
| Engelbrektson, V | 1 |
| Beermann, B | 1 |
| Yano, M | 1 |
| Buck, ML | 1 |
| van de Wal, RM | 1 |
| Asselbergs, FW | 1 |
| Plokker, HW | 1 |
| Smilde, TD | 1 |
| Lok, D | 1 |
| van Gilst, WH | 1 |
| Mohacsi, P | 1 |
| Katus, HA | 1 |
| Tendera, M | 1 |
| Rouleau, JL | 1 |
| Fowler, MB | 1 |
| Coats, AJ | 1 |
| Roecker, EB | 1 |
| Packer, M | 2 |
| Roik, M | 1 |
| Starczewska, MH | 1 |
| Stawicki, S | 1 |
| Huczek, Z | 1 |
| Kochanowski, J | 1 |
| Oreziak, A | 1 |
| Furmańczyk, A | 1 |
| Opolski, G | 1 |
| van der Horst, IC | 1 |
| Botoni, FA | 1 |
| Poole-Wilson, PA | 1 |
| Ribeiro, AL | 1 |
| Okonko, DO | 1 |
| Oliveira, BM | 1 |
| Pinto, AS | 1 |
| Teixeira, MM | 1 |
| Teixeira, AL | 1 |
| Reis, AM | 1 |
| Dantas, JB | 1 |
| Ferreira, CS | 1 |
| Tavares, WC | 1 |
| Rocha, MO | 1 |
| Stas, S | 1 |
| Whaley-Connell, A | 1 |
| Habibi, J | 1 |
| Appesh, L | 1 |
| Hayden, MR | 1 |
| Karuparthi, PR | 1 |
| Qazi, M | 1 |
| Morris, EM | 1 |
| Cooper, SA | 1 |
| Link, CD | 1 |
| Stump, C | 1 |
| Hay, M | 1 |
| Ferrario, C | 1 |
| Sowers, JR | 1 |
| Aleksandrowicz, E | 1 |
| Lysiak-Szydlowska, W | 1 |
| Rutishauser, W | 1 |
| Aumont, MC | 1 |
| Agnola, D | 1 |
| Juliard, JM | 1 |
| Karrillon, G | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Abosehmah-Albidy, AZ | 1 |
| York, P | 1 |
| Wong, V | 1 |
| Losowsky, MS | 1 |
| Chrystyn, H | 1 |
| Stepan, VM | 1 |
| Hammer, HF | 1 |
| Krejs, GJ | 1 |
| Schwinger, RH | 1 |
| Kjeldsen, KP | 1 |
| Nørgaard, A | 1 |
| Thygesen, K | 1 |
| Farquharson, CA | 1 |
| Henger, A | 1 |
| Tutt, P | 1 |
| Riesen, WF | 1 |
| Hulter, HN | 1 |
| Krapf, R | 1 |
| Alvarez, JS | 1 |
| Vílchez, FG | 1 |
| Chrysostomou, A | 1 |
| Becker, G | 1 |
| Beck, L | 1 |
| Blanc-Guillemaud, V | 1 |
| Cherif, OK | 1 |
| Jover, B | 1 |
| Davy, JM | 1 |
| Cicoira, M | 1 |
| Zanolla, L | 1 |
| Rossi, A | 1 |
| Golia, G | 1 |
| Franceschini, L | 1 |
| Brighetti, G | 1 |
| Marino, P | 1 |
| Zardini, P | 1 |
| Chowanetz, W | 1 |
| Rückert, KH | 1 |
| Juchems, R | 1 |
| Drozdova, ES | 1 |
| Komarov, FI | 1 |
| Daniliak, IG | 1 |
| Tuzel'baev, NK | 1 |
| Zamotaev, IP | 1 |
| Kabakov, AI | 1 |
| Jackson, L | 1 |
| Branch, R | 1 |
| Levine, D | 1 |
| Ramsay, L | 1 |
| Loginov, AS | 1 |
| Gladisch, W | 1 |
| Schmidt, W | 1 |
| Schnabel, KH | 1 |
| Schulz, V | 1 |
| Perchikova, GE | 1 |
| Tsibekmakher, TD | 1 |
| Kanemoto, N | 1 |
| Nakayama, K | 1 |
| Ide, M | 1 |
| Goto, Y | 1 |
| Potter, C | 1 |
| Willis, D | 1 |
| Sharp, HL | 1 |
| Scharzenberg, SJ | 1 |
| el-Zayadi, A | 1 |
| Mohran, Z | 1 |
| Hasseeb, N | 1 |
| Nagy, N | 1 |
| Dabbous, H | 1 |
| Andriulli, A | 1 |
| Arrigoni, A | 1 |
| Gindro, T | 1 |
| Karbowiak, I | 1 |
| Buzzetti, G | 1 |
| Armanini, D | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Pockros, PJ | 1 |
| Reynolds, TB | 1 |
| Boer, P | 1 |
| Koomans, HA | 1 |
| Hené, RJ | 1 |
| Geyskes, GG | 1 |
| Van Shaik, BA | 1 |
| Roos, JC | 1 |
| Dorhout Mees, EJ | 1 |
| Mertin, J | 1 |
| Koczorek, KR | 1 |
| Backmund, H | 1 |
| Kuntz, E | 1 |
| Rawlins, MD | 1 |
| Swales, JD | 1 |
| Thurston, H | 1 |
| Queiroz, FP | 1 |
| Tange, JD | 1 |
| Kremer, D | 1 |
| Fraser, R | 1 |
| Brown, JJ | 1 |
| Lever, AF | 1 |
| Davies, DL | 1 |
| Robertson, JI | 1 |
| Nolte, D | 1 |
| Sycheva, IM | 1 |
| Vinogradov, AV | 1 |
| Speranskaia, NV | 1 |
| Krater, AA | 1 |
| Ignatova, TA | 1 |
| Schüren, KP | 3 |
| Hüttemann, U | 3 |
| Wildhirt, E | 1 |
| Loggie, JM | 1 |
| Hillenbrand, P | 1 |
| Sherlock, S | 1 |
| Fanconi, A | 1 |
| Schachenmann, G | 1 |
| Nüssli, R | 1 |
| Prader, A | 1 |
| Steinitz, L | 1 |
| Schreiter, G | 1 |
| Nagasaka, M | 1 |
| Nakamura, K | 1 |
| Kinouchi, T | 1 |
| Kurosawa, T | 1 |
| Ito, T | 1 |
| Davis, DA | 1 |
| Medline, NM | 1 |
| Gentili, G | 1 |
| Liberti, R | 1 |
| Schneider, PJ | 1 |
| Eytel, CS | 1 |
| Weinreich, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.[NCT02344199] | 450 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction[NCT01955694] | Phase 2 | 72 participants (Actual) | Interventional | 2013-11-11 | Completed | ||
| Efficacy and Safety of Finerenone in Patients With Heart Failure With Reduced Ejection Fraction[NCT05974566] | 60 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systo[NCT01807221] | Phase 2 | 1,066 participants (Actual) | Interventional | 2013-06-17 | Completed | ||
| The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure[NCT00232180] | Phase 3 | 2,743 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients[NCT00868439] | Phase 2 | 120 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty[NCT04630132] | 1,500 participants (Anticipated) | Observational | 2017-03-25 | Recruiting | |||
| Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844] | 207 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy[NCT01996397] | 34 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102] | 15 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects[NCT01813201] | Phase 4 | 14 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure[NCT00180258] | Phase 2/Phase 3 | 2,200 participants | Interventional | 2000-01-31 | Completed | ||
| Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System[NCT00433043] | Phase 4 | 2 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Insufficient enrollment) | ||
| CRT-P or CRT-D in Patients With Dilated Cardiomyopathy and Heart Failure Without LGE-CMR High-risk Markers[NCT04139460] | 924 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study[NCT05491655] | 34 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | |||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response[NCT02541773] | 58 participants (Anticipated) | Observational | 2013-11-30 | Active, not recruiting | |||
| Pacemaker Induced Transient Dyssynchrony for Treating Heart Failure (PITA-HF): Feasibility, Safety, and Tolerability[NCT04159454] | 8 participants (Actual) | Interventional | 2020-11-20 | Completed | |||
| ElectroCRT - Left Ventricular Lead Implant and Optimization Guided by Electrocardiography in Cardiac Resynchronization Therapy[NCT02346097] | 122 participants (Actual) | Interventional | 2015-02-16 | Completed | |||
| Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy[NCT03356652] | 93 participants (Anticipated) | Interventional | 2018-03-08 | Recruiting | |||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy[NCT01557140] | Phase 4 | 42 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity[NCT02896309] | 45 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker[NCT00106561] | Phase 2/Phase 3 | 60 participants | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Baseline and Day 90
| Intervention | Percentage of participants (Number) |
|---|---|
| Eplerenone (INSPRA®) | 37.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 30.9 |
| Finerenone (BAY94-8862) 5-10 mg OD | 32.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 37.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 38.8 |
| Finerenone (BAY94-8862) 15-20 mg OD | 34.2 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter for mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 71.633 | -1.351 | -3.442 | -0.503 | -0.613 | -0.716 | -3.185 | -1.218 |
| Finerenone (BAY94-8862) 10-20 mg OD | 70.343 | -0.738 | -2.387 | -0.094 | 0.17 | -0.545 | -2.96 | -0.298 |
| Finerenone (BAY94-8862) 15-20 mg OD | 71.145 | -1.166 | -0.625 | -1.163 | -0.575 | -0.877 | -0.083 | -0.172 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 71.044 | -1.693 | -0.537 | 0.146 | -0.199 | -0.106 | 0.868 | 0.696 |
| Finerenone (BAY94-8862) 5-10 mg OD | 71.442 | -2.143 | 1.608 | -0.845 | -2.144 | -1.738 | -2.194 | -0.444 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 70.61 | 0.013 | -0.083 | -0.068 | -0.85 | -1.121 | 4.101 | -1.16 |
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state. (NCT01807221)
Timeframe: Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.58 | 0.06 | 0.08 | -0.12 | 0.06 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.56 | 0.06 | 0.1 | -0.05 | 0.07 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.59 | 0.02 | 0.06 | 0 | 0.04 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.59 | 0.02 | 0.03 | -0.06 | 0.01 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.62 | 0.02 | 0.04 | -0.09 | 0.01 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.58 | 0.07 | 0.08 | -0.1 | 0.08 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Beats per minute (Beats/min) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 74.957 | -0.8 | -3.109 | 0.294 | 0.297 | -0.189 | -2.278 | -1.281 |
| Finerenone (BAY94-8862) 10-20 mg OD | 73.852 | -0.548 | 0.423 | -0.802 | 0.192 | -0.71 | 4.733 | 0.834 |
| Finerenone (BAY94-8862) 15-20 mg OD | 74.329 | -1.176 | -3.969 | -1.633 | -1.608 | -1.145 | -2.072 | -1.317 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 73.369 | 1.073 | 0.599 | 1.064 | -0.975 | -1.647 | -1.424 | -2.057 |
| Finerenone (BAY94-8862) 5-10 mg OD | 72.681 | -0.63 | 1.842 | 0.435 | -1.741 | -2.89 | -0.222 | -0.626 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 74.184 | -0.719 | -1.324 | -0.349 | -2.318 | -2.212 | 1.101 | -1.326 |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points. (NCT01807221)
Timeframe: Baseline, Day 30 and Day 90
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Day 30 | Day 90 | |
| Eplerenone (INSPRA®) | 43.7 | 20.5 | 24.3 |
| Finerenone (BAY94-8862) 10-20 mg OD | 42.3 | 24.9 | 28.3 |
| Finerenone (BAY94-8862) 15-20 mg OD | 43.2 | 20.6 | 22.2 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 42.8 | 18.2 | 21.3 |
| Finerenone (BAY94-8862) 5-10 mg OD | 45.4 | 19.3 | 24.5 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 42.1 | 23 | 29.3 |
(NCT01807221)
Timeframe: Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimoles per liter (mmol/L) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 4.159 | 0.057 | 0.179 | 0.307 | 0.117 |
| Finerenone (BAY94-8862) 10-20 mg OD | 4.131 | 0.21 | 0.274 | 0.275 | 0.175 |
| Finerenone (BAY94-8862) 15-20 mg OD | 4.117 | 0.193 | 0.216 | 0.245 | 0.036 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 4.081 | 0.135 | 0.091 | 0.184 | 0.226 |
| Finerenone (BAY94-8862) 5-10 mg OD | 4.211 | 0.075 | 0.131 | 0.153 | 0.054 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 4.174 | 0.085 | 0.171 | 0.164 | 0.05 |
(NCT01807221)
Timeframe: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | millimeter of mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Day 7 | Day 14 | Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 120.554 | -0.541 | -3.442 | 0.067 | 0.684 | -0.967 | -2.991 | 0.188 |
| Finerenone (BAY94-8862) 10-20 mg OD | 116.024 | 0.162 | -3.099 | 1.786 | 0.981 | 1.216 | -2.32 | 2.041 |
| Finerenone (BAY94-8862) 15-20 mg OD | 116.941 | -0.546 | -2.906 | 0.899 | 0.667 | 0.956 | -0.028 | 3.037 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 119.492 | -3.178 | -4.488 | -0.824 | 0.337 | 0.922 | -0.41 | 2.869 |
| Finerenone (BAY94-8862) 5-10 mg OD | 118.498 | -2.565 | 4.142 | -0.367 | -1.249 | 0.047 | -2.167 | 1.95 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 119.087 | 0.568 | 1.241 | 0.374 | -1.811 | -0.664 | 9.391 | -0.928 |
Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight [i.e. date change] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 28 | 43 | 45 | 56 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 15 | 22 | 27 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 23 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 23 | 33 | 35 | 43 |
| Finerenone (BAY94-8862) 5-10 mg OD | 14 | 23 | 26 | 38 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 8 | 21 | 29 | 36 |
Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 6 | 7 | 9 | 15 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0 | 0 | 1 | 2 |
| Finerenone (BAY94-8862) 15-20 mg OD | 2 | 4 | 5 | 8 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 5 | 7 | 10 | 16 |
| Finerenone (BAY94-8862) 5-10 mg OD | 1 | 3 | 4 | 7 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 1 | 2 | 4 | 11 |
Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Follow-up | |
| Eplerenone (INSPRA®) | 21 | 35 | 37 | 47 |
| Finerenone (BAY94-8862) 10-20 mg OD | 7 | 14 | 18 | 26 |
| Finerenone (BAY94-8862) 15-20 mg OD | 15 | 22 | 28 | 34 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 19 | 30 | 32 | 40 |
| Finerenone (BAY94-8862) 5-10 mg OD | 12 | 20 | 22 | 30 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 9 | 17 | 24 | 30 |
B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.925 | 0.783 | 0.723 | 0.896 | 0.795 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.852 | 0.711 | 0.706 | 0.848 | 0.729 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.879 | 0.824 | 0.771 | 1.044 | 0.852 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.944 | 0.864 | 0.813 | 1.104 | 0.815 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.878 | 0.854 | 0.839 | 1.006 | 0.886 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.832 | 0.79 | 0.719 | 0.884 | 0.726 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT01807221)
Timeframe: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
| Intervention | Ratio (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Day 30 | Day 60 | Day 90 | Premature discontinuation | Follow-up | |
| Eplerenone (INSPRA®) | 0.883 | 0.749 | 0.688 | 0.948 | 0.747 |
| Finerenone (BAY94-8862) 10-20 mg OD | 0.822 | 0.748 | 0.728 | 1.133 | 0.746 |
| Finerenone (BAY94-8862) 15-20 mg OD | 0.921 | 0.829 | 0.771 | 0.965 | 0.849 |
| Finerenone (BAY94-8862) 2.5-5 mg OD | 0.98 | 0.822 | 0.789 | 1.369 | 0.747 |
| Finerenone (BAY94-8862) 5-10 mg OD | 0.874 | 0.814 | 0.765 | 1.267 | 0.887 |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 0.888 | 0.81 | 0.783 | 0.927 | 0.809 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 288 |
| Placebo: Double-blind Phase | 392 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010)
| Intervention | participants (Number) |
|---|---|
| Eplerenone: Double-blind Phase | 249 |
| Placebo: Double-blind Phase | 356 |
Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 408 | 463 |
| Placebo: Double-blind Phase | 491 | 552 |
Death due to any cause. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 171 | 205 |
| Placebo: Double-blind Phase | 213 | 253 |
Death due to any cause or hospitalization due to any cause. Hospitalization due to any cause is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 462 | 530 |
| Placebo: Double-blind Phase | 569 | 636 |
Death due to any cause or first of occurrence HF hospitalization. HF hospitalization is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 270 | 311 |
| Placebo: Double-blind Phase | 376 | 418 |
First occurrence of CV hospitalization. CV hospitalization is defined as hospitalization due to HF (first or subsequent), acute myocardial infarction, angina pectoris (unstable), cardiac arrhythmia (atrial fibrillation [AF], atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias), stroke/CVA, other CV reasons (such as hypotension or peripheral vascular disease), implantation of a cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) with CV event as the primary reason for hospitalization as determined by endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 304 | 346 |
| Placebo: Double-blind Phase | 399 | 439 |
CV mortality is defined as death due to heart failure, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident (CVA), other CV cause (such as aneurysm or pulmonary embolism). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 147 | 178 |
| Placebo: Double-blind Phase | 185 | 215 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 45 | 49 |
| Placebo: Double-blind Phase | 33 | 40 |
(NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 21 | 24 |
| Placebo: Double-blind Phase | 26 | 31 |
First occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 164 | 186 |
| Placebo: Double-blind Phase | 253 | 277 |
Death due to HF or first occurrence of HF hospitalization. Hospitalization due to HF is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF as the primary reason for hospitalization as determined by the endpoint committee adjudicator. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 170 | 194 |
| Placebo: Double-blind Phase | 262 | 287 |
First occurrence of hospitalization due to hyperkalemia. Hospitalization due to hyperkalemia is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization as determined by endpoint committee adjudicator. Hyperkalemia is defined as serum potassium level greater than (>) 5.5 milliequivalents per liter (mEq/L). (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 4 | 4 |
| Placebo: Double-blind Phase | 3 | 3 |
First occurrence of hospitalization due to worsening renal function. Hospitalization due to worsening renal function is defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization as determined by endpoint committee adjudicator. Worsening renal function is defined as doubling of serum creatinine level from baseline level. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 9 | 10 |
| Placebo: Double-blind Phase | 8 | 10 |
First occurrence of implantation of cardiac defibrillator (ICD). ICD is an electronic device capable of monitoring the heart rhythm. When the heart is beating normally, the device remains inactive. If the heart develops a life-threatening tachycardia, the ICD delivers electrical shocks to the heart to terminate the abnormal rhythm and return the heart rhythm to normal. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 61 | 76 |
| Placebo: Double-blind Phase | 59 | 78 |
First occurrence of implantation of resynchronization device. CRT is use of a specialized pacemaker to re-coordinate the action of the right and left ventricles in heart failure. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 1364, 1373) | Up to 59.5 months (complete DB) (n= 1367, 1376) | |
| Eplerenone: Double-blind Phase | 33 | 45 |
| Placebo: Double-blind Phase | 41 | 53 |
New onset of atrial fibrillation or flutter is defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization, where atrial fibrillation was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 950, 937) | Up to 59.5 months (complete DB) (n= 956, 940) | |
| Eplerenone: Double-blind Phase | 32 | 41 |
| Placebo: Double-blind Phase | 52 | 59 |
The definition of new onset diabetes mellitus is the diagnosis of diabetes mellitus in a participant after randomization, when DM was not present before randomization. (NCT00232180)
Timeframe: Baseline (30 March 2006) up to 50 months (cut-off date: 25 May 2010), 59.5 months (complete DB phase: 18 March 2011)
| Intervention | participants (Number) | |
|---|---|---|
| Up to 50 months (cut-off) (n= 904, 973) | Up to 59.5 months (complete DB) (n= 907, 975) | |
| Eplerenone: Double-blind Phase | 34 | 42 |
| Placebo: Double-blind Phase | 40 | 47 |
(NCT00868439)
Timeframe: Baseline and Day 28
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Patiromer | -0.21 |
| Placebo | 0.23 |
Analysis based on local laboratory data. (NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 0 |
| Placebo | 6.1 |
(NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 90.9 |
| Placebo | 73.5 |
Analysis based on central laboratory data. (NCT00868439)
Timeframe: 28 Days
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 7.3 |
| Placebo | 24.5 |
(NCT00868439)
Timeframe: Baseline and Day 28
| Intervention | percentage of participants (Number) |
|---|---|
| Patiromer | 12.7 |
| Placebo | 24.5 |
(NCT00868439)
Timeframe: 28 Days
| Intervention | days (Median) |
|---|---|
| Patiromer | NA |
| Placebo | NA |
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
18 reviews available for spironolactone and Chronic Illness
| Article | Year |
|---|---|
Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
Topics: Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Humans; Mineralocorticoid Receptor An | 2022 |
Eplerenone in chronic heart failure with depressed systolic function.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomiz | 2015 |
Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mine | 2010 |
Aldosterone-induced fibrosis in the kidney: questions and controversies.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Antihypertensive Agents; Blood Pressure; Child, | 2011 |
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2013 |
[Aldosterone and its antagonists in heart failure].
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
Diagnosis and management of heart failure in the long-term care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; | 2003 |
Drug therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2003 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
[Aldosterone antagonist therapy for chronic heart failure].
Topics: Aldosterone; Chronic Disease; Death, Sudden, Cardiac; Diuretics; Eplerenone; Fibrosis; Heart Failure | 2005 |
[Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Aldosterone; Chronic Disease; Contraindications; Eplerenone; Heart Failure; Humans; Mineralocorticoi | 2007 |
[Classic treatment of chronic heart insufficiency. What if new?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Digitalis Glycosides; Diuretics; Drug The | 1995 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Miner | 1999 |
[Hepatogenous (secondary) aldosteronism (author's transl)].
Topics: Aldosterone; Angiotensin II; Chronic Disease; Esophageal and Gastric Varices; Hepatitis; Hepatitis A | 1974 |
Variability in response to drugs.
Topics: Acute Disease; Acylation; Chlorthalidone; Chronic Disease; Depression; Diazoxide; Digoxin; Dose-Resp | 1974 |
Hypertension in children and adolescents. II. Drug therapy.
Topics: Age Factors; Antihypertensive Agents; Blood Pressure Determination; Child; Chlorothiazide; Chronic D | 1969 |
31 trials available for spironolactone and Chronic Illness
| Article | Year |
|---|---|
The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Topics: Chronic Disease; Eplerenone; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Anta | 2023 |
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Double-Blind M | 2018 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Furosemide; H | 2014 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; H | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mi | 2016 |
MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Epler | 2017 |
Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Chronic Disease; Double-Blind Method; Eplerenone; Fema | 2017 |
Influence of spironolactone therapy on thiamine blood levels in patients with heart failure.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Chronic Disease; Cross-Sectional Studies; Diuretic | 2008 |
Spironolactone attenuates oxidative stress in patients with chronic kidney disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidan | 2008 |
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2009 |
Spironolactone in chronic hemodialysis patients improves cardiac function.
Topics: Aged; Chronic Disease; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Hyperkalemia; | 2009 |
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effect
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind | 2010 |
Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Chronic Diseas | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Resistanc | 2011 |
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double | 2011 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Combin | 2004 |
[Angiotensin receptor blockers in heart failure. CHARM Study].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chaga | 2007 |
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclode | 1997 |
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Me | 2000 |
Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
Topics: Aged; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Exercise Tolerance; Female; Hear | 2002 |
[Use of verospiron in chronic nonspecific lung diseases].
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Lung Diseases; Ma | 1975 |
[Comparative evaluation of the effectiveness of diuretics].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Diuresis; Diur | 1976 |
Short-term course of corticosteroids in the treatment of resistant ascites complicating schistosomal liver disease.
Topics: Adolescent; Adult; Aged; Ascites; Chronic Disease; Diuresis; Drug Therapy, Combination; Female; Furo | 1991 |
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Canrenone; Chronic Disease; Clinical Trials as Topic; Double-B | 1989 |
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance | 1986 |
92 other studies available for spironolactone and Chronic Illness
| Article | Year |
|---|---|
Alterations in Glucose Metabolism During the Transition to Heart Failure: The Contribution of UCP-2.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Survival; Chronic Disease; Female; Glucose; Glucose Tran | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, A | 2020 |
Eplerenone for treatment of chronic central serous chorioretinopathy.
Topics: Administration, Oral; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Fluorescein Ang | 2021 |
Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Di | 2017 |
The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Topics: Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Eplerenone; Female; Humans; | 2016 |
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Femal | 2019 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 2019 |
Eplerenone and chronic heart failure. No comparison with spironolactone.
Topics: Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyperkalemia; Mineralo | 2013 |
Patients' interest overlooked.
Topics: Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironol | 2013 |
Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the MUSIC study cohort.
Topics: Aged; Chronic Disease; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Miner | 2013 |
[Spironolactone in dermatological treatment. On and off label indications].
Topics: Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects an | 2013 |
[Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
Topics: Acute Disease; Adult; Central Serous Chorioretinopathy; Chronic Disease; Dose-Response Relationship, | 2014 |
Aldosterone antagonists in systolic heart failure.
Topics: Chronic Disease; Eplerenone; Evidence-Based Medicine; Heart Failure, Systolic; Humans; Hyperkalemia; | 2014 |
Cost effectiveness of eplerenone in patients with chronic heart failure.
Topics: Age Factors; Aged; Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Female; Heart Fail | 2014 |
The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; | 2014 |
Developing a list of high-alert medications for patients with chronic diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Amiodarone; Analgesics, Opioid; Anti-Arrhythmi | 2014 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas | 2015 |
Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Topics: Administration, Oral; Adult; Aged; Central Serous Chorioretinopathy; Choroid; Chronic Disease; Epler | 2015 |
Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Topics: Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Fluorescein Angiography | 2016 |
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Topics: Aged; Aspirin; Blood Pressure; Chronic Disease; Drug Interactions; Eplerenone; Female; Glomerular Fi | 2016 |
Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Chronic Dise | 2016 |
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Topics: Australia; Chronic Disease; Cost-Benefit Analysis; Eplerenone; Heart Failure; Hospitalization; Human | 2016 |
[Eplerenone treatment in chronic central serous chorioretinopathy].
Topics: Adult; Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Humans; Male; Mi | 2016 |
Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Diuretics; Female; Heart Failure; Humans; | 2016 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; | 2016 |
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats.
Topics: Animals; Blood Pressure; Body Weight; Chronic Disease; Creatinine; Delayed Graft Function; Disease M | 2009 |
Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism.
Topics: Aldehydes; Aldosterone; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Dis | 2009 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Chronic Disease; Creatinine; Evidence-Based Medicine; Female; Hea | 2009 |
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
Topics: Aortic Diseases; Chronic Disease; Humans; Hyperkalemia; Hypertrophy, Left Ventricular; Kidney Diseas | 2009 |
Spironolactone therapy in heart failure patients with chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Creatinine; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Miner | 2009 |
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Chronic Disease; Diuretics; Follow-Up Studies; | 2009 |
Eplerenone in chronic renal disease: the EVALUATE trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Trials as Topic; Eplerenone; Female; Human | 2010 |
Gitelman's syndrome presenting as recurrent paralytic ileus due to chronic renal tubular K+ wasting.
Topics: Alkalosis; Bartter Syndrome; Calcium; Chronic Disease; Diagnosis, Differential; Diuretics; Gitelman | 2010 |
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Topics: Acute Kidney Injury; Aged; Alabama; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2012 |
Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Chronic Disease; Creatinine; Disease Models, Animal; Disease P | 2011 |
Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Chronic Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Heart F | 2013 |
Effects of spironolactone alone and in addition to a β-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Drug Therapy, Combination; Heart Failure; Mal | 2012 |
Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation.
Topics: Animals; Aortic Valve Insufficiency; Blood Pressure; Cardiomegaly; Chronic Disease; Diastole; Diseas | 2012 |
[Structural and functional changes in myocardium of patients with chronic heart failure treated with spironolactone].
Topics: Adult; Chronic Disease; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; | 2012 |
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Administration, Oral; Animals; Chronic Disease; Disease Models, Animal; Disease Progression; Dogs; E | 2002 |
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Topics: Aldosterone; Animals; Chronic Disease; Collagen Type I; Collagen Type IV; Cyclosporine; Fibronectins | 2003 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians.
Topics: Aged; Cardiology; Chronic Disease; Digoxin; Diuretics; Female; Guideline Adherence; Heart Failure; H | 2003 |
[CLINICAL TRIALS OF THE NEW ALDOSTERONE ANTAGONISTS OF A STEROID NATURE].
Topics: Adolescent; Chronic Disease; Diabetes Mellitus; Extremities; Familial Mediterranean Fever; Geriatric | 1964 |
Drug therapy in chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Diuretics; Drug Combinations; Heart Failu | 2004 |
Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
Topics: Age Factors; Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Creatinine; Female; Guideline | 2004 |
Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
Topics: Animals; Aorta; Apoptosis; Blood Pressure; Cell Size; Chronic Disease; Constriction, Pathologic; Dru | 2005 |
Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angio | 2005 |
Clinical experience with spironolactone in pediatrics.
Topics: Chronic Disease; Diagnosis-Related Groups; Diuretics; Female; Heart Diseases; Humans; Hyperkalemia; | 2005 |
High prevalence of microalbuminuria in chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti | 2005 |
[The place of aldosterone receptor blockers in the treatment of chronic heart failure].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2005 |
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Drug | 2006 |
[Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug T | 2006 |
Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic | 2007 |
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Topics: Animals; Animals, Genetically Modified; Blood Pressure; Cardiomegaly; Chronic Disease; Fibrosis; Mag | 2007 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics.
Topics: Chronic Disease; Diarrhea; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperaldosteronism; Hyper | 1997 |
Drugs for chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 1999 |
[The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
Topics: Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlle | 1999 |
[Chronic heart insufficiency should be treated also with spironolactone].
Topics: Chronic Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 1999 |
Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients.
Topics: Acid-Base Equilibrium; Acidosis; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Chronic D | 2000 |
[Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
Topics: Chronic Disease; Cost-Benefit Analysis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonist | 2001 |
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug Therapy, Combination; E | 2001 |
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Mo | 2001 |
[Therapy of the bronchitic syndrome in the elderly].
Topics: Aged; Aging; Anti-Bacterial Agents; Breathing Exercises; Bronchitis; Chronic Disease; Cromolyn Sodiu | 1977 |
[Disorder of the mineralocorticoid function of the adrenals in the acute period of myocardial infarct and the ways for its correction].
Topics: Acute Disease; Adrenal Gland Diseases; Adult; Aged; Aldosterone; Chronic Disease; Coronary Disease; | 1979 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseas | 1977 |
[Treatment of chronic diseases of the liver].
Topics: Adrenal Cortex Hormones; Chronic Disease; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Phenob | 1977 |
[Effect of Aldadiene potassium on pulmonary gas exchange in chronic obstructive pulmonary diseases].
Topics: Adult; Aged; Asthma; Bronchitis; Carbon Dioxide; Chronic Disease; Female; Humans; Lung; Male; Middle | 1977 |
[Treatment of refractory chronic circulatory insufficiency].
Topics: Adult; Aged; Benzothiadiazines; Cardiac Glycosides; Cardiomyopathies; Chronic Disease; Coronary Dise | 1976 |
Giant negative U waves in a patient with uncontrolled hypertension and severe hypokalemia.
Topics: Aged; Chronic Disease; Combined Modality Therapy; Drug Therapy, Combination; Electrocardiography; Fe | 1992 |
Primary and secondary amenorrhea associated with spironolactone therapy in chronic liver disease.
Topics: Adolescent; Adult; Amenorrhea; Cholestasis; Chronic Disease; Female; Humans; Hypertension, Portal; H | 1992 |
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.
Topics: Amiloride; Ascites; Body Weight; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans; | 1986 |
Blood to interstitial fluid volume ratio in chronic hypokalaemic states.
Topics: Bartter Syndrome; Blood Volume; Chlorthalidone; Chronic Disease; Extracellular Space; Female; Humans | 1985 |
[Pilot study on the efficacy of high doses of aldosterone and spirolactone derivatives in the treatment of multiple sclerosis].
Topics: Adult; Aldosterone; Blood Pressure Determination; Body Weight; Chronic Disease; Electrocardiography; | 1972 |
Faecal sodium-potassium ratio and aldosteronism in experimental hypertension in the rat.
Topics: Animals; Chronic Disease; Feces; Female; Hyperaldosteronism; Hypertension; Kidney; Nephrectomy; Pota | 1972 |
Amiloride in primary hyperaldosteronism with chronic peptic ulceration.
Topics: Aged; Amiloride; Bicarbonates; Blood Pressure; Body Water; Chlorides; Chronic Disease; Diuretics; Fe | 1973 |
[Spironolactone effect and the lung].
Topics: Blood Gas Analysis; Chronic Disease; Humans; Respiratory Insufficiency; Spironolactone; Ventilation- | 1973 |
[Changes in water-salt metabolism in cardiac insufficiency under the influence of diuretic preparations].
Topics: Adult; Aged; Arteriosclerosis; Body Fluids; Chronic Disease; Coronary Disease; Diet Therapy; Ethacry | 1973 |
[Cardiac therapy of chronic bronchitis (author's transl)].
Topics: Acetazolamide; Bloodletting; Bronchitis; Chronic Disease; Digitalis Glycosides; Diuretics; Hemodynam | 1974 |
[Aldosteronism in liver diseases].
Topics: Acute Disease; Aldosterone; Chronic Disease; Humans; Hyperaldosteronism; Liver Diseases; Spironolact | 1974 |
[Aldactone (spironolactone, canrenoate-K) in the treatment of chronic cor pulmonale].
Topics: Administration, Oral; Aged; Arteries; Carbon Dioxide; Chronic Disease; Drug Combinations; Female; He | 1972 |
[Cardiac-pulmonary effects of aldactone in chronic cor pulmonale].
Topics: Acid-Base Equilibrium; Aged; Blood Gas Analysis; Blood Pressure; Bronchitis; Cardiac Output; Chronic | 1972 |
Use of metolazone in the treatment of ascites due to liver disease.
Topics: Adult; Ascites; Chlorides; Chronic Disease; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypok | 1971 |
Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ("Bartter's syndrome"), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment.
Topics: Alkalosis; Calcium; Child; Chronic Disease; Female; Growth Disorders; Humans; Hyperaldosteronism; Hy | 1971 |
[Amyloidosis in childhood].
Topics: Amyloidosis; Child; Chronic Disease; Encephalomyelitis; Furosemide; Humans; Male; Nephrotic Syndrome | 1971 |
The effects of aldosterone and spirolactone on renal sodium and potassium excretion during mannitol diuresis.
Topics: Aldosterone; Alkalies; Animals; Chronic Disease; Diuresis; Dogs; Female; Humans; Injections, Intrave | 1968 |
Spironolactone (aldactone) bodies: concentric lamellar formations in the adrenal cortices of patients treated with spironolactone.
Topics: Adrenal Glands; Adult; Aged; Chronic Disease; Cytoplasmic Granules; Female; Heart Failure; Heart Neo | 1970 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
The nephrotic syndrome in an elderly woman. An unusual association with an unusual response to therapy.
Topics: Aged; Biopsy; Body Weight; Chronic Disease; Diagnosis, Differential; Edema; Female; Humans; Hydrochl | 1969 |
[Portal hypertension in chronic liver diseases and its therapy].
Topics: Ascites; Chronic Disease; Esophageal and Gastric Varices; Humans; Hypertension, Portal; Liver Cirrho | 1969 |